Introduction
============

An estimated 1.8 million new lung cancer cases occurred in 2012, accounting for \~13% of total cancer diagnoses ([@b1-ol-0-0-6916]). During this time period, lung cancer was the most frequently diagnosed type of cancer and the leading cause of cancer-associated mortality among males; among females, it was the leading cause of cancer-associated mortality in more developed countries and the second leading cause of cancer-associated mortality in less developed countries ([@b1-ol-0-0-6916]). In 2011, lung cancer exhibited the highest morbidity and mortality rates among all cancer types in China ([@b2-ol-0-0-6916]).

Abundant supplies of resources and energy are essential for malignant proliferation. The pentose phosphate pathway, the only pathway for *de novo* ribose synthesis, has been identified as a tumor therapeutic target ([@b3-ol-0-0-6916]--[@b5-ol-0-0-6916]). The pentose phosphate pathway consists of an oxidative pathway and a non-oxidative pathway ([@b6-ol-0-0-6916]). In the oxidative pathway, by oxidative decarboxylation, glucose 6-phosphate is irreversibly converted into ribose 5-phosphate used for the synthesis of nucleotides, and two NADPH molecules are produced as reducing equivalents ([@b6-ol-0-0-6916]). The non-oxidative pathway joins the pentose phosphate pathway to glycolysis, and spare ribose or pentose molecules are reversibly transformed into glyceraldehyde 3-phosphate and fructose 6-phosphate by transketolase (TKT) and transaldolase (TAL), without restriction of the irreversible oxidative signaling pathway ([@b6-ol-0-0-6916]). A previous study revealed the upregulation of TKT activity in various types of cancer *in vivo* and *in vitro* ([@b3-ol-0-0-6916]). Our previous study demonstrated that oxythiamine exerts its anticancer effect via the inhibition of thiamine-dependent enzymes, particularly TKT ([@b7-ol-0-0-6916]).

RNA interference (RNAi) technology provides an advantageous platform for investigating the function of a given gene. Prior to RNAi technology, gene knockout was the main research tool in reverse genetics. However, RNAi technology, using siRNA or short hairpin RNA expression vectors to knockdown target genes in a sequence-specific way, may be more time-efficient, economic and convenient and is therefore an attractive tool for gene function exploration, particularly within cancer research fields ([@b8-ol-0-0-6916]). In the present study, siRNA vectors were applied with cationic liposomes to investigate the influence of the *TKT* gene on the metabolism of A549 cells.

Materials and methods
=====================

### Reagents and equipment

The following reagents and equipment were used in the present study: Gibco fetal bovine serum (FBS; Thermo Fisher Scientific, Inc., Waltham, MA, USA); Dulbecco\'s modified Eagle\'s medium (DMEM; Genom Biotech Pvt., Ltd., Mumbai, India); three types of TKT-specific siRNA duplex sequences and negative-control siRNA duplex sequence (catalog no. A10001) and transfection reagents (siRNA-Mate; catalog no. G04003; Shanghai GenePharma Co., Ltd., Shanghai, China); polymerase chain reaction (PCR) primers, as presented in [Table I](#tI-ol-0-0-6916){ref-type="table"} (Shanghai Sangon Pharmaceutical Co., Ltd., Shanghai, China); quantitative (q)PCR reaction kit (UltraSYBR Mixture; catalog no. CW0957; CWBiotech Co. Ltd., Beijing, China) and cell cycle detection kit (catalog no. CW2575S, CWBiotech Co. Ltd.); Cell Counting Kit-8 (CCK-8; Beyotime Institute of Biotechnology, Haimen, China); Transwell chambers and cell culture dishes (Corning Incorporated, Corning, NY, USA); Mastercycler ep realplex cycler (Eppendorf, Hamburg, Germany); FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA); NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Inc.).

### Cell culture

The A549 lung cancer cell line was provided by Zhongshan Hospital Central Laboratory of Fudan University (Shanghai, China). A549 cells were cultured in DMEM supplemented with 10% FBS, penicillin (100 kU/l) and streptomycin (100 kU/l) in a humidified incubator at 37°C and 5% CO~2~.

### siRNAs

The sequences of the siRNAs used in the present study were as follows: TKT-siRNA-A sense, 5′-CCGGCAAAUACUUCGACAATT-3′; antisense, 5′-UUGUCGAAGUAUUUGCCGGTT-3′. TKT-siRNA-B sense, 5′-GCAUCUAUAAGCUGGACAATT-3′; antisense, 5′-UUGUCCAGCUUAUAGAUGCTT-3′. TKT-siRNA-C sense, 5′-CCAGCCAACAGCCAUCAUUTT-3′; antisense, 5′-AAUGAUGGCUGUUGGCUGGTT-3′. Negative control siRNA and fluorescein amidite (FAM)-negative control siRNA sense, 5′-UUCUCCGAACGUGUCACGUTT-3′; antisense, 5′-ACGUGACACGUUCGGAGAATT-3′.

### Transfection

FAM-labelled siRNA (0, 25, 50 and 75 nM) was transfected into A549 cells to determine the optimal transfection concentration. Cells were transfected with siRNAs when cell confluence 30--50%, according to the manufacturer\'s protocol. FAM-siRNA (25 µM; 0, 2.2, 4.4 and 6.6 µl) was added into 200 µl DMEM solution for 5 min and, subsequently, 8 µl siRNA-mate was mixed into the solution for 30 min. During this time, siRNA-siRNA-mate complexes were generated. During this procedure, cell culture medium was replaced with 2 ml DMEM with serum (Gibco; Thermo Fisher Scientific, Inc.). The siRNA-siRNA-mate complexes were added to the cells and incubated for 6--8 h at 37°C. Cells were digested with trypsin (Genom Biotech Pvt., Ltd.) for 2 min at room temperature, centrifuged at 1,000 × g for 5 min at room temperature and washed with ice-cold PBS (Genom Biotech Pvt., Ltd.) twice at room temperature. For each cell suspension, ≥10,000 events were analyzed using a FACSCalibur flow cytometer and FlowJo software (version 7.6.1; Tree Star, Inc., Ashland, OR, USA) for data analysis. To determine the most effective transfection sequence, six groups were assessed and compared: Blank control (DMEM only), mock control (DMEM and siRNA mate), negative control (negative control siRNA), TKT-siRNA-A, TKT-siRNA-B and TKT-siRNA-C. Reverse transcription (RT-)qPCR was used to determine the TKT mRNA expression levels.

### Reverse transcription (RT)-qPCR

Total RNA was extracted from the cells using TRIzol^®^ reagent (CWBiotech Co. Ltd.). The quantity and integrity of mRNA was validated using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, Inc.) and gDNA Eraser was used to erase the genomic DNA at 42°C for 2 min. Subsequently, HiFiScript cDNA Synthesis kit (catalog no. CW2569; CWBiotech Co. Ltd.) was used to reverse transcribe 1 µg total RNA at 37°C for 15 min and 85°C for 5 sec into cDNA. qPCR was performed using a Mastercycler ep realplex cycler with SYBR^®^ Green Master Mix (catalog no. CW0957; CWBiotech Co. Ltd.). Primers for TKT, glucose-6-phosphate dehydrogenase (G6PDH), TAL, phosphoribosyl pyrophosphate synthetase 1 (PRPS1), sorbitol dehydrogenase (SORD), hexokinase 1 (HK1), transketolase-like 1 (TKTL1), transketolase-like 2 (TKTL2) and β-actin were used, and the details are listed in [Table I](#tI-ol-0-0-6916){ref-type="table"}. The amplification procedure consisted of 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 60 sec. Each sample was performed in triplicate. The quantification cycle (Cq) values of the target genes were normalized to the housekeeping gene β-actin, and relative expression levels were compared according to the 2^−ΔΔCq^ method ([@b9-ol-0-0-6916]).

### CCK-8 assay

Following a 72-h transfection, cells were seeded into 96-well plates (2,000 cells/per well) and incubated for 24, 48 and 72 h at 37°C in an atmosphere containing 5% CO~2~. Following incubation, 10 µl CCK-8 solution was added to the wells, according to the manufacturer\'s protocol. Following a further 2 h incubation, optical density (OD) was evaluated at 450 nm, which provided an indirect indication of the number of viable cells.

### Cell cycle analysis

Following 72 h transfection, cells (when confluence reached more than 90%) were digested by trypsin (Genom Biotech Pvt., Ltd.) for 2 min at room temperature, centrifuged at 1,000 × g for 5 min at room temperature and washed with ice-cold PBS (Genom Biotech Pvt., Ltd.) twice at room temperature. Cells were fixed with 75% ethanol overnight at 4°C and subsequently dyed with propidium iodide for 30 min at 37°C in the dark. For each cell suspension, ≥10,000 events were analyzed using a FACSCalibur flow cytometer and FlowJo software (version 7.6.1; Tree Star, Inc., Ashland, OR, USA) for data analysis.

### Wound healing

Following 72 h transfection, 2×10^6^ cells were seeded into 6-well plates. When the confluence reached 100%, linear wounds were created using a sterile 10 µl plastic pipette tip and serum-free medium was added. Following 0, 6, 12 and 24 h incubations at 37°C in an atmosphere containing 5% CO~2~, the wounds were imaged using an inverted microscope (Olympus, Japan) under bright-field illumination. ImageJ software (version 1.48u; National Institutes of Health) was used to calculate the width of wounds.

### Transwell migration assay

Following a 72 h transfection, 1.0×10^5^ cells in 100 µl serum-free medium were added to the upper compartment of each Transwell chamber and 600 µl DMEM supplemented with 10% FBS was added into each of the lower compartments. Following a 12 h incubation at 37°C in an atmosphere containing 5% CO~2~, cells that had penetrated the membrane were dyed with 0.1% crystal violet for 20 min. Five randomly selected fields of view were observed using a microscope (magnification, ×10 and ×20; DP72; Olympus, Japan) under bright-field illumination and cells that penetrated the Transwell chamber membrane (violet dying) were counted. The mean number of cells of each image was calculated for each group including the blank group, negative-siRNA group and siRNA-C group.

### Statistical analysis

Data are presented as the mean ± standard deviation. Each experiment was repeated three times at least. The results were analyzed using SPSS version 19.0 software (IBM Corp., Armonk, NY, USA). The significance of differences was determined using one-way analysis of variance with post hoc least significant difference, or Dunnett\'s t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Optimization of the transfection sequence and concentration

[Fig. 1A](#f1-ol-0-0-6916){ref-type="fig"} presents the flow cytometry results from cells transfected with FAM-labelled negative control siRNA at four different concentrations. The maximum transfection efficiency (88%) was achieved at a concentration of 50 nmol/l ([Fig. 1B](#f1-ol-0-0-6916){ref-type="fig"}). [Fig. 1C](#f1-ol-0-0-6916){ref-type="fig"} presents the fluorescence and light microscopic images of the same field of view in cells transfected with 50 nmol/l siRNA.

[Fig. 2A](#f2-ol-0-0-6916){ref-type="fig"} presents the *TKT* expression levels at 48 h of cell transfected with the three *TKT*-specific siRNAs or negative control siRNA. Compared with negative control group, the knockdown efficiency of siRNA-C was the highest (*TKT* expression level, 0.35 relative to the negative control group). [Fig. 2B](#f2-ol-0-0-6916){ref-type="fig"} presents the *TKT* expression levels at 72 h in cells transfected with various concentrations of siRNA-C. The results demonstrated that a concentration of 50 nmol/l achieved the greatest efficiency (*TKT* expression level, 0.21 relative to the negative control group), and this was in agreement with the flow cytometric analysis.

### TKT knockdown decreases cell viability and induces cell cycle arrest

[Fig. 3A](#f3-ol-0-0-6916){ref-type="fig"} presents the cell viability of A549 cells following a 72-h transfection. After 24 h, the viability of cells transfected with siRNA-C was significantly reduced compared with the negative control group \[OD values (mean ± standard deviation) of siRNA-C group vs. negative control group were 0.2984±0.0371 vs. 0.0952±0.0063 (P\<0.0001) for 24 h; 0.5582±0.0090 vs. 0.1817±0.0037 (P\<0.0001) for 48 h; 1.3663±0.0833 vs. 0.3519±0.0175 (P\<0.0001)\] for 72 h. This indicated that downregulation of the *TKT* gene decreased the viability of A549 cells.

[Fig. 3B](#f3-ol-0-0-6916){ref-type="fig"} presents the cell cycle distribution of the negative control and siRNA-C groups. The proportions of cells in G~1~/G~0~ phase in the negative control and siRNA-C groups were 56.51±2.0 and 70±2.5%, respectively (P=0.002). The proportions of cells in G~2~/M and S phases were 43.49±2.0 and 30±2.5% (P=0.002), respectively. This suggests that the downregulation of *TKT* may arrest the cell cycle of A549 cells in G~1~/G~0~ phase.

### TKT knockdown decreases cell migration

Compared with the negative control group, the wound healing ability of cells in the siRNA-C group decreased markedly ([Fig. 4A](#f4-ol-0-0-6916){ref-type="fig"}); following a 24-h healing period, the wound sizes of the negative control vs. siRNA-C groups were 254.71±34.96 vs. 349.12±37.43 µm (P=0.0001). In the Transwell migration assay ([Fig. 4B](#f4-ol-0-0-6916){ref-type="fig"}), the number of cells that migrated through the membrane was significantly decreased in the siRNA-C group compared with the negative control group (150±49.0/field vs. 250±47.8/field, respectively; P\<0.0001). This indicated that downregulation of *TKT* may inhibit cell migration in A549 lung cancer cells.

### TKT knockdown decreases the mRNA expression levels of other metabolism-associated genes

As the key enzyme of the non-oxidative pathway, a decreased expression level of *TKT* can influence the expression levels of other key metabolic enzymes. The knockdown of *TKT* induced the downregulation of *G6PDH*, *TAL*, *PRPS1*, *SORD* and *HK1* mRNA in A549 cells ([Fig. 5](#f5-ol-0-0-6916){ref-type="fig"}).

### Detection of TKT family genes

The human *TKT* gene family includes *TKT*, *TKTL1* and *TKTL2* ([@b9-ol-0-0-6916]). In the present study, the mRNA expression levels of *TKTL1* and *TKTL2* were detected in untreated A549 lung cancer cells using RT-qPCR. The results revealed that the Cq values of *TKT, TKTL1-1, TKTL1-2, TKTL1-3 and TKTL2* were 20.73±1.35, 31.97±1.71, 33.42±1.33, 34.71±0.79, respectively. This indicated that the expression levels of *TKTL1* and *TKTL2* mRNAs are low or absent in these cells.

Discussion
==========

The non-oxidative pathway mediated by TKT exploits the intermediates of glycolysis to synthesize ribose phosphate reversibly ([@b6-ol-0-0-6916]). A previous study confirmed that the non-oxidative pathway serves a vital role in malignant cell proliferation and metabolism ([@b10-ol-0-0-6916]). High activity and expression levels of TKT have been identified in multiple tumor types ([@b11-ol-0-0-6916]). Furthermore, enhanced TKT activity may be a biomarker for tumor relapse and metastasis, indicating a poor prognosis ([@b12-ol-0-0-6916]).

The results of the present study indicated that the downregulation of *TKT* and decrease of ribose reduced A549 cell proliferation rate markedly, and arrested cell cycle at the G~1~/G~0~ phase. Targeting metabolic enzymes has great potential as an anticancer therapy. As a coenzyme of TKT, thiamine (vitamin B1) may be a target for tumor therapy, and its analogues, oxythiamine and pyrithiamine, have been demonstrated to inhibit tumor growth significantly ([@b4-ol-0-0-6916],[@b13-ol-0-0-6916]). However, thiamine is also a coenzyme for pyruvate dehydrogenase and ketoglutarate dehydrogenase, which are key enzymes of the Krebs cycle. Furthermore, thiamine deficiency may affect thiamine-dependent enzymes dysfunction to various degrees and transketolase is the most vulnerable, induced by thiamine deficiency compared with other thiamine-dependent enzymes (pyruvate dehydrogenase and ketoglutarate dehydrogenase) ([@b14-ol-0-0-6916]). Previous studies have revealed that numerous natural compounds, including sugiol and epicatechin gallate, may inhibit cancer cell growth via the disturbance of TKT ([@b15-ol-0-0-6916],[@b16-ol-0-0-6916]). In the present study, TKT-siRNA inhibited A549 cell growth via G~0~/G~1~ cell cycle arrest, in agreement with previous experiments, and decreased the expression of *G6PDH* mRNA, which is the key enzyme of the oxidative signaling pathway. Jung *et al* ([@b16-ol-0-0-6916]) examined intracellular glutathione expression levels in *TKT*-knockdown cells, and revealed that glutathione levels were decreased, which induced reactive oxygen species production in DU145 cells. Thus, the presence of TKT was necessary for the production of the antioxidant enzyme NADPH and *TKT* knockdown increased reactive oxygen species generation, which may induce inflammation-injury ([@b16-ol-0-0-6916]).

*TKT* is associated with numerous metabolic signaling pathways, including the polyol pathway, which includes SORD as its key enzyme ([@b17-ol-0-0-6916]). *SORD* expression was revealed to be decreased in *TKT*-knockdown cells in the present study. The polyol pathway provides substantial fructose for entry into the non-oxidative signaling pathway. When the non-oxidative pathway is inhibited, metabolites accumulate, fructose demand is reduced and *SORD* expression decreases. [Fig. 6](#f6-ol-0-0-6916){ref-type="fig"} presents the pentose phosphate pathway and its associated metabolic signaling pathways.

The human *TKT* gene family includes three members: *TKT*, *TKTL1* and *TKTL2*. *TKTL1* was considered to be a pseudogene until Coy *et al* ([@b18-ol-0-0-6916]) identified its encoded protein and named it in 2005; however, there are controversies over the results of previous studies on *TKTL1* ([@b19-ol-0-0-6916],[@b20-ol-0-0-6916]), and whether *TKTL1* can be regarded as a potential tumor marker requires further data for validation.

In conclusion, silencing *TKT* mRNA expression by RNAi can inhibit A549 lung cancer cell proliferation and cell migration, induce cell cycle arrest, and lead to the downregulation of other metabolic enzyme mRNAs. *TKT* may be a potential target for tumor therapy in the future. Further research investigating the mechanism underlying oncotherapy mediated by RNAi may provide a powerful tool for clinical application.
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![Optimization of the transfection concentration. (A) Four concentrations of FAM-labelled siRNA assessed by flow cytometry: (a) 0, (b) 25, (c) 50 and (d) 75 nmol/l. (B) Percentage of fluorescent cells (M1) in the four concentration groups; a maximum transfection efficiency of 88±8% was achieved at 50 nmol/l. (C) Microscopic images of cells transfected with 50 nmol/l siRNA (magnification, ×400): (a) Fluorescence and (b) light microscopic images of the same field of view. \*P\<0.05. FAM, fluorescein amidite; siRNA, small interfering RNA; FL1-H, the cell stained by FAM.](ol-14-05-5906-g00){#f1-ol-0-0-6916}

![Selection of siRNA sequences for *TKT* knockdown. (A) *TKT* expression levels (relative to negative control) of cells transfected with the three *TKT*-specific siRNAs. (B) *TKT* expression levels (relative to negative control) of cells transfected with TKT-siRNA-C at various concentrations (25--100 nmol/l). The TKT mRNA expression levels were measured using RT-qPCR. \*P\<0.05. siRNA, small interfering RNA; TKT, transketolase; RT-qPCR, reverse transcriptase-quantitative polymerase chain reaction; C-25, 25 nmol/l siRNA-C; C-50, 50 nmol/l siRNA-C; C-75, 75 nmol/l siRNA-C; C-100, 100 nmol/l siRNA-C.](ol-14-05-5906-g01){#f2-ol-0-0-6916}

![Effect of *TKT* expression on cell viability and the cell cycle. (A) Cell viability (measured as OD) at 24, 48 and 72 h in cells transfected with siRNAs targeting *TKT*, and cells in the blank and negative control groups. (B) Cell cycle distribution in (a) cells transfected with negative control siRNA and (b) cells transfected with siRNA-C targeting *TKT*. \*P\<0.05. TKT, transketolase; OD, optical density; siRNA, small interfering RNA.](ol-14-05-5906-g02){#f3-ol-0-0-6916}

![Representative images and quantified results of wound healing and Transwell migration assays. (A) Wound healing assay results at 0, 6, 12 and 24 h in blank control, negative control and siRNA-C groups (magnification, ×200). (B) Migrated cells on the membrane following Transwell migration assay in blank control, negative control and siRNA-C groups (magnification, ×400). \*P\<0.05. siRNA-C, small interfering RNA targeting transketolase.](ol-14-05-5906-g03){#f4-ol-0-0-6916}

![mRNA expression levels of *TKT* and other key metabolic enzymes determined by reverse transcription-quantitative polymerase chain reaction. Relative to the negative control group (set as 1.0), the expression levels of *TKT*, *G6PDH*, *TAL*, *SORD, PRPS1* and *HK1* were 0.19, 0.44, 0.66, 0.52, 0.66 and 0.53, respectively. Results are presented as the mean ± standard deviation. Each sample was performed in triplicate. TKT, transketolase; TAL, transaldolase; G6PDH, glucose-6-phosphate dehydrogenase; PRPS1, phosphoribosyl pyrophosphate synthetase 1; SORD, sorbitol dehydrogenase; HK1, hexokinase 1.](ol-14-05-5906-g04){#f5-ol-0-0-6916}

![Pentose phosphate pathway (dotted lines) and associated metabolic pathways (solid lines). TKT, transketolase; TAL, transaldolase; G6PDH, glucose-6-phosphate dehydrogenase; HK, hexokinase; AR, aldose reductase; SORD, sorbitol dehydrogenase; Glc, glucose; G6P, glucose 6-phosphate; F6P, fructose 6-phosphate; R5P, ribose 5-phosphate; G3P, glyceraldehyde 3-phosphate; E4P, erythrose 4-phosphate; S7P, sedoheptulose 7-phosphate; X5P, xylulose 5-phosphate; R5P\', ribulose 5-phosphate; NADP, nicotinamide-adenine dinucleotide phosphate; NADPH, reduced NADP; PRPS1, phosphoribosyl pyrophosphate synthetase 1.](ol-14-05-5906-g05){#f6-ol-0-0-6916}

###### 

Polymerase chain reaction primers.

  Primer    Sequence (5 to 3)               Product length
  --------- ------------------------------- ----------------
  β-actin   F: TGACGTGGACATCCGCAAAG         205 kb
            R: CTGGAAGGTGGACAGCGAGG         
  TKT       F: TACCCAAGTGATGGCGTTGC         129 kb
            R: GACCTGGAAGTCCTCATTGTTGTTAT   
  G6PDH     F: TGTTGTCCCGGTTCCAGATG         217 bp
            R: TGCATGAGCCAGATAGGCTG         
  TAL       F: ATGGTGAGGAAGTCACAGCC         201 bp
            R: ATTTGTTGGGCGCATCCTTG         
  SORD      F: AAGACCTCATTTGGGCCTGG         92 bp
            R: AAGCCCAACAACCTTTCCCT         
  HK1       F: TTATCACGCAGGCGGTTCA          147 bp
            R: TGCCAAAGAAATCCTGACCC         
  PRPS1     F: TGCGAGAAATAGCAGGACCG         263 bp
            R: CCAGGAGACCTGAGTGACCT         
  TKTL1-1   F: ACTAATGGCGGATGCTGAGG         153 bp
            R: CATGATGTAGGGTGGCCGGA         
  TKTL1-2   F: ATGGCTCGGACAAGGACTGG         191 bp
            R: GGCGGTTCACATCAAAGATTGC       
  TKTL1-3   F: AAACTTGCCCCGAGTCCAC          125 bp
            R: GGTAAGGAATGCAGGGCTCA         
  TKTL2     F: ATCCATTCCATCAGGGCCAC         175 bp
            R: GGATAGGAGCAGCATGTCCC         

TKT, transketolase; G6PDH, glucose-6-phosphate dehydrogenase; TAL, transaldolase; SORD, sorbitol dehydrogenase; HK1, hexokinase; PRPS1, phosphoribosyl pyrophosphate synthetase 1; TKTL, transketolase-like; F, forward; R, reverse.
